The startup develops neuromodulation devices and software that deliver targeted electrical stimulation to specific brain and spinal cord areas, providing a less invasive treatment option for patients with chronic diseases. This technology enhances therapeutic effectiveness and expands access to care for a broader patient population.
Funding
Funding not disclosed
Founders
Product
Problem
Many chronic diseases lack effective treatments that can precisely target affected areas of the brain and spinal cord without invasive procedures. Existing therapies may have limited effectiveness or pose significant risks and side effects, leaving a large patient population with unmet clinical needs.
Solution
iVEAcare is developing next-generation neuromodulation technology platforms that deliver targeted electrical stimulation to specific areas of the brain and spinal cord. This approach offers a less invasive alternative for treating chronic diseases by enhancing therapeutic effectiveness and expanding access to care. The company's focus is on creating innovative therapies that address unmet clinical needs impacting large patient populations, with the goal of improving patient outcomes through advanced neuromodulation techniques.
Target Audience
The primary target audience includes patients suffering from chronic diseases who require targeted neuromodulation therapies, as well as physicians and clinicians seeking less invasive treatment options.
Features
- Development of implantable medical devices for targeted neuromodulation
- Focus on treating chronic diseases through electrical stimulation of the brain and spinal cord
- Clinical program design for Class III products, including pre-clinical and clinical evaluations
- Expertise in obtaining FDA PMA, EU/UK CE Mark (MDR), and TGA approvals
- Cloud & backend development for scalable and efficient solutions
- Implementation of cybersecurity best practices for medical applications